Muestra la distribución de la producción WoS, Scopus y SciELO del autor.
Publicaciones WoS (Ediciones: ISSHP, ISTP, AHCI, SSCI, SCI), Scopus, SciELO Chile.
| Firmas del autor | |
| Nombre | CARRASCO, PAULA |
| Género | Mujer |
| Área Principal WOS | Medicine, General & Internal; Environmental Sciences; Meteorology & Atmospheric Sciences; |
| Afiliación Principal | Pontificia Universidad Católica De Chile |
Publicaciones en Chile
Citas Totales
Afiliaciones Chilenas
| WOS | #Pub |
|---|---|
| Medicine, General & Internal | 3 |
| Environmental Sciences | 1 |
| Meteorology & Atmospheric Sciences | 1 |
| Clinical Neurology | 1 |
| Oncology | 1 |
| Scopus | #Pub |
|---|---|
| Medicine (All) | 3 |
| SciELO | #Pub |
|---|---|
| Health Sciences | 3 |
| Institución | # Pub |
|---|---|
| Pontificia Universidad Católica De Chile | 3 |
| Universidad De Chile | 1 |
| Clínica Alemana | 1 |
| Fdn Arturo Lopez Perez | 1 |
| Fundación Arturo López Pérez | 1 |
| Escritora | 1 |
| Año | Firma | Institución (Incites asoc.) | H Index | Average Percentile | Impact Citation | Impact Relative World | Impact Journal Normalized Citation | Impact Category Normalized Citation | Percentage Cited | Percentage Top 1 | Percentage Top 10 | Percentage Journal Q1 | Percentage Journal Q2 | Percentage Journal Q3 | Percentage Journal Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2019 | Carrasco A, Paola | Pontificia Universidad Catolica de Chile | 0.0 | 100.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| 2019 | Carrasco G, Paulo | Pontificia Universidad Catolica de Chile | 0.0 | 100.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| 2019 | Carrasco, Paula | Clinica Alemana | 0.0 | 100.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 100.0 | 0.0 | 0.0 | 0.0 |
| Palabra Clave | #Pub |
|---|---|
| quality feedback | 1 |
| gallbladder neoplasms | 1 |
| generalized additive model | 1 |
| hiv | 1 |
| immunological | 1 |
| information and communication technologies | 1 |
| intervention | 1 |
| lockdown | 1 |
| men | 1 |
| mobile sources | 1 |
| nitrogen oxides | 1 |
| ozone | 1 |
| pancreatic-cancer | 1 |
| perioperative management | 1 |
| phase-i trial | 1 |
| qualitative research | 1 |
| full-dose gemcitabine | 1 |
| radiation-therapy | 1 |
| radiotherapy | 1 |
| randomized-trial | 1 |
| resection | 1 |
| risk | 1 |
| sex | 1 |
| stents | 1 |
| surgery | 1 |
| tanzania | 1 |
| thoracic surgery | 1 |
| thrombosis | 1 |
| tract cancer | 1 |
| vehicular emissions | 1 |
| writing | 1 |
| burden | 1 |
| adjuvant radiotherapy | 1 |
| adjuvants | 1 |
| aerosols | 1 |
| aids | 1 |
| aids serodiagnosis | 1 |
| aids serology | 1 |
| air-quality | 1 |
| angioplasty | 1 |
| antiplatelet therapy | 1 |
| artery stents | 1 |
| aspirin | 1 |
| balloon | 1 |
| barriers | 1 |
| breast-cancer | 1 |
| acceptability | 1 |
| carcinoma | 1 |
| cardiac risk | 1 |
| chemoradio therapy | 1 |
| chemoradiotherapy | 1 |
| city | 1 |
| clinical-outcomes | 1 |
| clopidogrel use | 1 |
| concurrent chemotherapy | 1 |
| coronary | 1 |
| coronary artery disease | 1 |
| drug therapy | 1 |
| drug-eluting stents | 1 |
| evolution | 1 |
| feedback | 1 |